MUC1 and neoplasm: A small number of tumor patients treated with tumor vaccine against MUC1 or anti-PD-L1 monoclonal antibody alone have good clinical efficacy, but there are still many patients who do not respond to such single-target targeting or checkpoint blockade therapies, or whose efficacy is short-lived and unable to stimulate a durable anti-tumor immune response and strong tumor control and regression.